Jeffrey H. Chen

3.3k total citations · 3 hit papers
7 papers, 1.6k citations indexed

About

Jeffrey H. Chen is a scholar working on Molecular Biology, Organic Chemistry and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jeffrey H. Chen has authored 7 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 2 papers in Organic Chemistry and 2 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jeffrey H. Chen's work include PI3K/AKT/mTOR signaling in cancer (4 papers), Renal cell carcinoma treatment (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). Jeffrey H. Chen is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (4 papers), Renal cell carcinoma treatment (2 papers) and Angiogenesis and VEGF in Cancer (2 papers). Jeffrey H. Chen collaborates with scholars based in United States and China. Jeffrey H. Chen's co-authors include Brion W. Murray, Robert S. Kania, Michele McTigue, James Solowiej, Yali Deng, Anjali Babbar, Pingda Ren, Tess Ely, Matthew R. Janes and Lian‐Sheng Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Cancer Research and Clinical Cancer Research.

In The Last Decade

Jeffrey H. Chen

7 papers receiving 1.5k citations

Hit Papers

Selective Inhibition of Oncogenic KRAS Output wi... 2008 2026 2014 2020 2016 2008 2012 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State
    2016 530 citations Matthew P. Patricelli, Matthew R. Janes et al. Cancer Discovery profile →
  2. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3
    2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →
  3. Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors
    2012 451 citations Michele McTigue, Brion W. Murray et al. Proceedings of the National Academy of Sciences profile →

Peers

Jeffrey H. Chen
Elaine S. E. Stokes United Kingdom
Lian‐Sheng Li United States
Mingfeng Yu Australia
Patrick A. Plé United Kingdom
Akihiko Tsuruoka Japan
Y.N. Vashisht Gopal United States
Nathan T. Ihle United States
James Tsai United States
Lily L. Remsing Rix United States
Giorgio Caravatti Switzerland
Elaine S. E. Stokes United Kingdom
Jeffrey H. Chen
Citations per year, relative to Jeffrey H. Chen Jeffrey H. Chen (= 1×) peers Elaine S. E. Stokes

Countries citing papers authored by Jeffrey H. Chen

Since Specialization
Citations

This map shows the geographic impact of Jeffrey H. Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey H. Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey H. Chen more than expected).

Fields of papers citing papers by Jeffrey H. Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey H. Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey H. Chen. The network helps show where Jeffrey H. Chen may publish in the future.

Co-authorship network of co-authors of Jeffrey H. Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey H. Chen. A scholar is included among the top collaborators of Jeffrey H. Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey H. Chen. Jeffrey H. Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

7 of 7 papers shown
1.
Patricelli, Matthew P., Matthew R. Janes, Lian‐Sheng Li, et al.. (2016). Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discovery. 6(3). 316–329. 530 indexed citations breakdown →
2.
Solowiej, James, Jeffrey H. Chen, Helen Y. Zou, Stephan K. Grant, & Brion W. Murray. (2013). Substrate-Specific Conformational Regulation of the Receptor Tyrosine Kinase VEGFR2 Catalytic Domain. ACS Chemical Biology. 8(5). 978–986. 4 indexed citations
3.
McTigue, Michele, Brion W. Murray, Jeffrey H. Chen, et al.. (2012). Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors. Proceedings of the National Academy of Sciences. 109(45). 18281–18289. 451 indexed citations breakdown →
4.
Zhu, JinJiang, Graham L. Smith, Min-Jean Yin, et al.. (2011). Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity. ACS Medicinal Chemistry Letters. 2(11). 809–813. 23 indexed citations
5.
Li, Gang, Lianglin Zhang, Enhong Chen, et al.. (2010). Dual Functional Monoclonal Antibody PF-04605412 Targets Integrin α5β1 and Elicits Potent Antibody-Dependent Cellular Cytotoxicity. Cancer Research. 70(24). 10243–10254. 20 indexed citations
6.
Liu, Kevin K.‐C., Xiao‐Jun Huang, Shubha Bagrodia, et al.. (2010). Quinazolines with intra-molecular hydrogen bonding scaffold (iMHBS) as PI3K/mTOR dual inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(4). 1270–1274. 26 indexed citations
7.
Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elaine S. E. Stokes Breakdown of academic impact, for papers by Lian‐Sheng Li Breakdown of academic impact, for papers by Mingfeng Yu Breakdown of academic impact, for papers by Patrick A. Plé Breakdown of academic impact, for papers by Akihiko Tsuruoka Breakdown of academic impact, for papers by Y.N. Vashisht Gopal Breakdown of academic impact, for papers by Nathan T. Ihle Breakdown of academic impact, for papers by James Tsai Breakdown of academic impact, for papers by Lily L. Remsing Rix Breakdown of academic impact, for papers by Giorgio Caravatti
Rankless by CCL
2026